Online citations, reference lists, and bibliographies.
← Back to Search

Multicentric Study On Malignant Pleural Mesothelioma In Turkey: Clinicopathologic And Survival Characteristics Of 282 Patients

E. T. Elkıran, M. A. Kaplan, A. Sevinç, S. Aksoy, U. Demirci, M. Seker, H. Harputluoğlu, N. Ozdemir, F. Işik, A. Ulaş, M. Inanç, U. Arslan, G. Dogu, A. Isikdogan, S. Buyukberber, Anatolian Society of Medical Oncology Group
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma (MPM) is a relatively rare, but aggressive tumor that causes high mortality. The major risk factor involved in the etiology is environmental and occupational exposure to asbestos. The optimal modality of therapy is controversial. The present study retrospectively evaluated the data pertinent to 282 patients who were examined and treated in 11 different medical oncology centers in Turkey. There were 161 males (57.1 %) and 121 females (42.9 %), with a mean age of 56.38 ± 12.07 years. Surgery was used in 74 patients, 21 patients (28.4 %) received only chemotherapy and 28 patients (37.8 %) received chemoradiotherapy after surgery. The median survival in patients who were administered adjuvant therapy after surgery was 24 months, while the median survival in patients who had only surgery was 6 months (p = 0.029). 106 patients were administered pemetrexed-platinum combination and 35 patients were administered gemcitabine-platinum combination as front-line chemotherapy. Median survival, 1- and 2-year survival rates in patients who received platinum analogues and pemetrexed or gemcitabine combinations were found statistically similar (p = 0.15). The median survival for all patients with MPM in our study was 18 months. The main factors influencing the overall survival were stage of the disease (p = 0.020), performance status (p < 0.001), asbestos exposure (p = 0.030) and mesothelioma histological subtypes (p < 0.001). Results of our study suggest that multi-modality treatment regimens consisting of surgery, radiotherapy and chemotherapy prolong overall survival. Survival rates in patients who received combining platinum analogues with pemetrexed or gemcitabine as front-line chemotherapy were found similar.
This paper references
10.1016/J.EJCTS.2006.11.046
A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.
M. Lucchi (2007)
10.1378/CHEST.70.1.43
Pleural calcification associated with exposure to chrysotile asbestos in southeast Turkey.
S. Yazicioglu (1976)
10.1016/0169-5002(95)00508-0
A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.
V. Rusch (1996)
Systemic drug therapy of malignant pleural mesothelioma.
A. Ardizzoni (1998)
10.1136/oem.45.12.838
An epidemiological study in an Anatolian village environmentally exposed to tremolite asbestos.
Y. Bariş (1988)
10.1016/S0025-6196(12)60212-2
Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases.
U. Prakash (1985)
10.1378/CHEST.107.6_SUPPLEMENT.345S
Mesothelioma and radical multimodality therapy: who benefits?
D. Sugarbaker (1995)
10.1183/09031936.98.12040972
Malignant pleural mesothelioma.
C. Boutin (1998)
10.1002/1097-0142(19861001)58:7<1540::AID-CNCR2820580727>3.0.CO;2-5
Diffuse malignant mesothelioma of pleura: Diagnosis and survival in 92 cases
V. Adams (1986)
10.1378/CHEST.99.1.191
New developments in asbestos-induced pleural disease.
D. Schwartz (1991)
10.1097/01.JTO.0000283754.00846.9C
P1-140: Outcomes with a platinum plus gemcitabine or pemetrexed as first-line systemic therapy for malignant pleural mesothelioma in British Columbia: a review of province-wide practice
C. Lee (2007)
10.1080/00039896.1982.10667559
Environmental fiber-induced pleuro-pulmonary diseases in an Anatolian village: an epidemiologic study.
M. Artvinli (1982)
10.1016/J.THORSURG.2004.06.007
Pathology of mesothelioma.
J. M. Corson (2004)
10.1159/000056289
Incidence of Malignant Pleural Mesothelioma due to Environmental Asbestos Fiber Exposure in the Southeast of Turkey
A. Şenyiğit (2000)
10.1016/S0140-6736(08)60727-8
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
10.1016/S0169-5002(97)80156-0
779 Malignant pleural mesothelioma in childhood: A case report
M. Gülhan (1997)
10.1183/9031936.99.14225899
Malignant mesothelioma and erionite exposure.
Z. Selçuk (1999)
Malignant Pleural Mesothelioma Caused by Environmental Exposure to Asbestos in the Southeast of Turkey : CT Findings in 117 Patients
H. Leblebı̇cı̇a (2000)
10.1002/1097-0142(19820601)49:11<2431::AID-CNCR2820491134>3.0.CO;2-W
Malignant mesothelioma of the pleura: Review of 123 patients
J. Brenner (1982)
10.1016/j.ejcts.2007.09.044
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
P. Borasio (2008)
10.1378/CHEST.111.1.106
The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
A. Renshaw (1997)
10.1378/CHEST.102.3.790
Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases.
Z. Selçuk (1992)
10.1007/s12199-007-0017-6
Pathology of mesothelioma
K. Inai (2008)
10.1007/s00063-002-1181-5
Prognose, Staging und Therapie des malignen Pleuramesothelioms
W. Neumeister (2002)
10.1378/CHEST.93.1.159
Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients.
E. Chailleux (1988)
Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey
ZT Selcuk (1992)
10.1183/09031936.99.13352399
Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort.
M. Metintas (1999)
10.1016/S0378-4274(01)00507-0
Lung diseases due to environmental exposures to erionite and asbestos in Turkey.
S. Emri (2002)
[Prognosis, staging and therapy of malignant pleural mesothelioma].
W. Neumeister (2002)
159–62
Dabouis G Pioche D de Lajartre M de Lajartre AY Rembeaux A Chailleux E (2012)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/S0954-6111(99)90318-9
Environmental asbestos exposure and malignant pleural mesothelioma.
M. Metintas (1999)
10.6004/JNCCN.2012.0006
[Malignant pleural mesothelioma].
Q. Kong (1983)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1378/CHEST.113.1_SUPPLEMENT.61S
Multimodality management of malignant pleural mesothelioma.
D. Sugarbaker (1998)
10.1159/000056288
Malignant Pleural Mesotheliomas: An Environmental Health Risk in Southeast Turkey
K. Müller (2000)
10.1002/cncr.11405
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma
A. Favaretto (2003)
10.1002/1097-0142(19930715)72:2<394::AID-CNCR2820720214>3.0.CO;2-5
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging
C. Boutin (1993)
10.1002/AJIM.4700190310
Fibrous zeolite (erionite)-related diseases in Turkey.
Baris Yi (1991)
10.1200/JCO.1999.17.1.25
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
10.1183/09031936.96.09061206
Malignant pleural mesothelioma from nonoccupational asbestos exposure in Metsovo (north-west Greece): slow end of an epidemic?
K. Sakellariou (1996)
10.1080/10408440903044928
Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through 2005
B. Price (2009)
10.1016/0007-0971(83)90068-2
Malignant mesothelioma 1982: review of 4710 published cases.
G. Hillerdal (1983)
10.1016/B978-0-443-06694-8.50081-6
Tumors of the Pleura and Mediastinum
M. Sovak (2008)
10.1097/JTO.0b013e318070ccaf
State of the Art: Pleuroscopy
P. Lee (2007)
10.1097/01.coc.0000144852.75613.56
Cisplatin and Gemcitabine in Malignant Pleural Mesothelioma: A Phase II Study
B. Castagneto (2005)
10.1002/IJC.2910390104
Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: A four‐year study in the cappadocian region of turkey
I. Bariş (1987)
10.1053/RMED.2001.1178
Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics.
M. Metintas (2001)
10.1016/S0169-5002(02)00180-0
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
10.1111/j.1749-6632.1979.tb18744.x
ENVIRONMENTAL MESOTHELIOMA IN TURKEY
Y. Bariş (1979)
10.1016/c2015-0-05400-4
Abeloff's Clinical Oncology
J. Niederhuber (2013)
10.1200/JCO.1988.6.1.147
Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985.
K. Antman (1988)
10.1097/JTO.0b013e31817c73d6
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
10.1016/S0025-6196(12)65411-1
Malignant mesothelioma of the pleura.
R. J. Pisani (1988)
10.1016/j.athoracsur.2009.05.036
Trimodality therapy for malignant pleural mesothelioma.
G. Buduhan (2009)
10.1183/09031936.01.17509220
The role of environmental and occupational exposures in Turkish immigrants with fibre-related disease.
P. Dumortier (2001)
10.1378/CHEST.126.4.1318
Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies.
M. Pistolesi (2004)
10.1002/1097-0142(19860515)57:10<1905::AID-CNCR2820571003>3.0.CO;2-J
Mesothelioma and mineral fibers
J. Wagner (1986)
Mesothelioma and mineral fibers. Cancer
JC Wagner (1986)
10.1002/1097-0142(19930715)72:2<389::AID-CNCR2820720213>3.0.CO;2-V
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis
C. Boutin (1993)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1136/THX.52.6.507
Malignant mesothelioma in south east England: clinicopathological experience of 272 cases.
D. Yates (1997)
10.1378/CHEST.122.6.2224
Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area.
S. Metintaş (2002)
Latency periods in asbestos-related mesothelioma of the pleura.
C. Bianchi (1997)
10.1080/01913120252959227
Malignant Mesothelioma and Occupational Exposure to Asbestos: A Clinicopathological Correlation of 1445 Cases
V. Roggli (2002)
10.1634/THEONCOLOGIST.4-6-488
Contemporary management of malignant pleural mesothelioma.
E. Butchart (1999)
10.3109/9781439802014-13
Malignant mesothelioma.
B. Robinson (2005)
10.1038/sj.bjc.6600505
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
10.1002/PATH.1711430303
Diagnosis of pleural malignant mesothelioma in life—a practical approach
D. Whitaker (1984)
10.1378/CHEST.125.3.1103
Asbestos and the pleura: a review.
D. Cugell (2004)
10.1136/thx.37.11.816
Pleural biopsy in the diagnosis of malignant mesothelioma.
A. Herbert (1982)
10.1586/14737140.8.2.293
Current concepts in malignant pleural mesothelioma
A. Kaufman (2008)
10.1038/ncponc0839
Malignant pleural mesothelioma: current concepts in treatment
A. Tsiouris (2007)
10.1111/j.1752-699X.2008.00046.x
Current concepts in chemotherapy for malignant pleural mesothelioma
J. Sørensen (2008)
10.1159/000196043
Diagnosis and prognostic factors in malignant pleural mesothelioma: a retrospective analysis of sixty-five patients.
L. Tammilehto (1992)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar